A new long-acting liposomal topical antifungal formula: Human clinical study

Cornea

Volumn 31, Issue 2, 2012, Pages 126-129

  Abdel Rhaman, Mohamed S ^a   Soliman, Wael ^a   Habib, Fawzia ^b   Fathalla, Dina ^b  

^a Faculty of Medicine   (Egypt)

^b University of Assiut   (Egypt)

Author keywords

Candida keratitis; fluconazole liposomal formulation

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA KERATITIS; CANDIDIASIS; CLINICAL ARTICLE; CONTROLLED DRUG RELEASE; CORNEA PERFORATION; CORNEA ULCER; DIABETES MELLITUS; DISEASE COURSE; DRUG FORMULATION; FEMALE; HUMAN; KERATITIS; KERATOPLASTY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCAR FORMATION; TREATMENT RESPONSE; VISUAL ACUITY; WOUND HEALING;

ADMINISTRATION, TOPICAL; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; EYE INFECTIONS, FUNGAL; FEMALE; FLUCONAZOLE; HUMANS; KERATITIS; LIPOSOMES; MALE; MIDDLE AGED;

EID: 84855834934     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e318221cf12     Document Type: Article

References (17)

1. O'Day DM. Orally administered antifungal therapy for experimental keratomycosis. Trans Am Ophthalmol Soc. 1990;88:685-725.
2. Klotz SA, Penn CC, Negvesky GJ, et al. Fungal and parasitic infections of the eye. Clin Microbiol Rev. 2000;13:662-685.
3. Al-Hussaini AK, Daef EAE, El-Shanawany AA, et al. Etiology of microbial keratitis. Bull Ophthalmol Soc Egypt. 1994;87:647-652.
4. Lin HC, Hsiao CH, Ma DH, et al. Medical treatment for combined Fusarium and Acanthamoeba keratitis. Acta Ophthalmol. 2009;87:199-203.
5. Frezard F. Liposomes: from biophysics to the design of peptide vaccines. Braz J Med Biol Res. 1999;32:181-189. (Pubitemid 29098198)
6. Kaur IP, Garg A, Singla AK, et al. Vesicular systems in ocular drug delivery: an overview. Int J Pharm. 2004;269:1-14. (Pubitemid 38035207)
7. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. Antimicrob Agents Chemother. 1994;38:1422-1424. (Pubitemid 24170733)
8. Mahdy RA, Nada WM, Wageh MM, et al. Assessment safety and efficacy of a combination therapy of topical amphotericin B and subconjunctival fluconazole for the treatment of fungal keratitis. Cutan Ocul Toxicol. 2010;29:193-197.
9. Abbasoglu OE, Hosal BM, Sener B, et al. Penetration of topical fluconazole into human aqueous humor. Exp Eye Res. 2001;72:147-151. (Pubitemid 32976978)
10. Habib FS, Fouad EA, Abdel-Rhaman MS, et al. Liposomes as an ocular delivery system of fluconazole: in-vitro studies. Acta Ophthalmol. 2010; 88:901-904.
11. Szoka F Jr, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A. 1978;75:4194-4198. (Pubitemid 9025976)
12. Ozdek SC, Miller D, Flynn PM, et al. In vitro antifungal activity of the fourth generation fluoroquinolones against Candida isolates from human ocular infections. Ocul Immunol Inflamm. 2006;14:347-351. (Pubitemid 44949893)
13. Panda A, Sharma N, Angra SK. Topical fluconazole therapy of Candida keratitis. Cornea. 1996;15:373-375. (Pubitemid 26189977)
14. Stevens DA. The new generation of antifungal drugs. Eur J Clin Microbiol Infect Dis. 1988;7:732-735. (Pubitemid 19017155)
15. Behrens-Baumann W, Klinge B, Ruchel R. Topical fluconazole for experimental Candida keratitis in rabbits. Br J Ophthalmol. 1990;74:40-42. (Pubitemid 20026679)
16. Schreiber W, Olbrisch A, Vorwerk CK, et al. Combined topical fluconazole and corticosteroid treatment for experimental Candida albicans keratomycosis. Invest Ophthalmol Vis Sci. 2003;44:2634-2643. (Pubitemid 36618424)
17. Oh YK, Nix DE, Straubinger RM. Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection. Antimicrob Agents Chemother. 1995;39:2104-2111.